While there are currently no approved disease -modifying therapies to treat progressive MS, results from a recent Phase III trail could change that landscape. In a press announcement by Genentech, a member of the Roche Group, the company announced that the experiental monoclonal antibody, ocrelizumb, significantly slowed progression of disability compared to placebo in a Phase II trial involving 732 people with primary progressive MS. Additional data from the trial will be reported at the…